Attached files

file filename
10-Q - FORM 10-Q - INTERCEPT PHARMACEUTICALS INCv328744_10q.htm
EX-31.1 - EXHIBIT 31.1 - INTERCEPT PHARMACEUTICALS INCv328744_31-1.htm
EX-31.2 - EXHIBIT 31.2 - INTERCEPT PHARMACEUTICALS INCv328744_31-2.htm

 

 

 

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Intercept Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his or her knowledge:

 

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

             
Date: November 26, 2012       By:   /s/ Mark Pruzanski
            Mark Pruzanski, M.D.
            President and Chief Executive Officer
            (Principal Executive Officer)

 

             
Date: November 26, 2012       By:   /s/ Barbara Duncani
            Barbara Duncan
            Chief Financial Officer
            (Principal Financial Officer)